W

Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871

Watchlist Manager
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Watchlist
Price: 11.71 CNY -0.26% Market Closed
Market Cap: 1.9B CNY
Have any thoughts about
Wuhan Hvsen Biotechnology Co Ltd?
Write Note

Wuhan Hvsen Biotechnology Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Wuhan Hvsen Biotechnology Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
W
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Cash from Operating Activities
ÂĄ92.9m
CAGR 3-Years
24%
CAGR 5-Years
35%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Operating Activities
ÂĄ3.1B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Operating Activities
ÂĄ1.2B
CAGR 3-Years
25%
CAGR 5-Years
-6%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Operating Activities
ÂĄ7.9B
CAGR 3-Years
39%
CAGR 5-Years
19%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Operating Activities
ÂĄ5B
CAGR 3-Years
-10%
CAGR 5-Years
65%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Operating Activities
-ÂĄ615.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Wuhan Hvsen Biotechnology Co Ltd
Glance View

Market Cap
1.9B CNY
Industry
Pharmaceuticals

HVSEN Biotechnology Co., Ltd. engages in the research and development, production, and sale of veterinary drugs. The company is headquartered in Wuhan, Hubei and currently employs 828 full-time employees. The company went IPO on 2020-08-24. The Company’s main products include veterinary active pharmaceutical ingredients, veterinary chemical preparations, veterinary traditional Chinese medicine preparations, feed and additives and environmental improvers, such as tyvanicin tartrate, florfenicol powder, banqing granules and piglet composites pre-mixed feed, etc. The firm mainly conducts its businesses in the China market.

Intrinsic Value
22.35 CNY
Undervaluation 48%
Intrinsic Value
Price
W

See Also

What is Wuhan Hvsen Biotechnology Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
92.9m CNY

Based on the financial report for Dec 31, 2023, Wuhan Hvsen Biotechnology Co Ltd's Cash from Operating Activities amounts to 92.9m CNY.

What is Wuhan Hvsen Biotechnology Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
35%

Over the last year, the Cash from Operating Activities growth was -4%. The average annual Cash from Operating Activities growth rates for Wuhan Hvsen Biotechnology Co Ltd have been 24% over the past three years , 35% over the past five years .

Back to Top